RenovoRx Inc. has announced that new clinical data from a pharmacokinetic $(PK)$ and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI). The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine $(IAG)$ delivered via the Trans-Arterial Micro-Perfusion (TAMP) therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622085-en) on January 08, 2026, and is solely responsible for the information contained therein.